PACIRA BIOSCIENCES, INC. Payments to Acquire Equity Method Investments
PACIRA BIOSCIENCES, INC. (PCRX) reported Payments to Acquire Equity Method Investments of $1.16 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireEquityMethodInvestments · last filed 2021-03-01
- PACIRA BIOSCIENCES, INC. payments to acquire equity method investments for the quarter ending 2020-12-31 was $1.16M.
- PACIRA BIOSCIENCES, INC. payments to acquire equity method investments for the quarter ending 2020-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. payments to acquire equity method investments for the quarter ending 2019-12-31 was $0.00.
- PACIRA BIOSCIENCES, INC. payments to acquire equity method investments for the quarter ending 2019-09-30 was $0.00.
- PACIRA BIOSCIENCES, INC. payments to acquire equity method investments for fiscal 2020 was $1.16M, a 28.48% decline from fiscal 2019.
- PACIRA BIOSCIENCES, INC. payments to acquire equity method investments for fiscal 2019 was $1.62M.
- PACIRA BIOSCIENCES, INC. payments to acquire equity method investments for fiscal 2018 was $0.00.
| Period end | Payments to Acquire Equity Method Investments 3 month | Payments to Acquire Equity Method Investments 6 month | Payments to Acquire Equity Method Investments 9 month | Payments to Acquire Equity Method Investments 12 month |
|---|---|---|---|---|
| 2020-12-31 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $1.16M derived: sum of 2 quarters · filed 2021-03-01 | $1.16M 10-K · filed 2021-03-01 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $0.00 10-Q · filed 2020-10-30 | ||
| 2020-06-30 | $0.00 10-Q · filed 2020-08-06 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $1.62M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-30 | $1.62M 10-Q · filed 2020-10-30 | ||
| 2019-06-30 | $1.62M 10-Q · filed 2020-08-06 | |||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $0.00 derived: sum of 2 quarters · filed 2021-03-01 | $0.00 10-K · filed 2021-03-01 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $0.00 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |